Previous post Next post

Covid: 67% of Geneva now has Antibodies

Vaccination has pushed the percentage of residents in Geneva with antibodies against the SARS-CoV-2 virus up to 67%, according to a recent study by Geneva’s HUG hospital.

© Kukotaekaterina |

To some extent, Geneva has been at the forefront of Switzerland’s experience with Covid-19. Since the beginning of the pandemic, the canton has recorded Switzerland’s highest rate of infection, 54% above the Swiss average.

Geneva has also been a leader on vaccination. By 11 July 2021, with 102 doses administered per 100 residents, Geneva trailed only the canton of Basel-City (105) on vaccination roll out. The Swiss average was 95 doses per 100 people.

Geneva’s high rates of infection and vaccination appear to have combined to deliver a high rate SARS-CoV-2 antibodies (67%) in the population.

Given Geneva’s high rate of infection and lead on vaccinations, it is likely that the level of SARS-CoV-2 antibodies in other Swiss cantons is lower than Geneva’s 67%.

Reflecting the age-based priority of the vaccination rollout, among the sample of 3,121 Geneva residents tested, 95% of those aged over 75 and 85% of those aged 50 to 65 had antibodies. Further down the age spectrum the percentages fell to 60% of those aged 18 to 50, 40% of those aged 12 to 15, 35% of those aged 6 to 12 and 25% of those under 6 years old.

It is highly likely that the virus will continue to circulate among the young and a vaccination programme aimed at this group to cut transmission would make sense, according to an expert at the hospital.

Full story here Are you the author?
About Le News
Le News
The newspaper Le News is a free, quality, local English language newspaper launched on 31 October 2013. Le News fills a gap in local Swiss media for the numerous English-speakers living and visiting Switzerland. In late January 2015 we decided to put our print medium on hold and focus on our digital media presence.
Previous post See more for 3) Swiss Markets and News Next post
Tags: ,,,,,

Permanent link to this article:

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.